Breaking News, Promotions & Moves

Matica Bio Names Paul Kim as CEO

Kim offers early three decades of experience across the CDMO, CRO and R&D biopharma sectors.

Author Image

By: Charlie Sternberg

Associate Editor

Matica Biotechnology Inc. (Matica Bio), a contract development and manufacturing organization (CDMO) of cell and gene therapies (CGTs), has appointed Paul Kim as chief executive officer.   As incoming CEO, Kim will manage daily operations and provide strategic direction to Matica Bio as it rapidly expands its capacity and capabilities in the U.S. and Korea. Yun Jeong Song, outgoing president and CEO, will take on a new role as president of Matica Holdings. About Paul Kim Kim brings to Mat...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters